Abstract

This application requests funding for the Eastern Cooperative Oncology Group (ECOG) Operations Office, as outlined in the narrative section of this application. Funding is requested to support the group administrative activities, protocol development and translational science, funding for Disease, Committee, Modality Chairs and the ECOG Core laboratories.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA021115-34S1
Application #
7681391
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1992-09-01
Project End
2010-04-30
Budget Start
2008-06-28
Budget End
2009-04-30
Support Year
34
Fiscal Year
2008
Total Cost
$61,182
Indirect Cost

  Institution

Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Sebastian, Sinto; Zhu, Yuan X; Braggio, Esteban et al. (2017) Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood 129:991-1007

Showing the most recent 10 out of 753 publications